Linked Life Data

11569529

Source:http://linkedlifedata.com/resource/pubmed/id/11569529

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8-9
pubmed:dateCreated
2001-9-24
pubmed:abstractText
1. The technique of accelerator mass spectrometry (AMS) is outlined. 2. The use of AMS in an initial validation study in animals is outlined. As part of the validation of the technique, samples from the animal study were analysed by both liquid scintillation counting (LSC) and, following dilution, by AMS. The results were similar. 3. The use of AMS in support of a clinical study is described. Six healthy male human volunteers were administered 2.7 mg [14C]-GI1817771 (121 Bq; 3.3nCi) to produce an exposure to ionizing radiation of 0.06 microSv. Mass balance in recovery of administered radioactivity was achieved and information about the presence of systemically circulating metabolites was gained. 4. The future potential of the technique of AMS is discussed.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0049-8254
pubmed:author
pubmed:issnType
Print
pubmed:volume
31
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
619-32
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:articleTitle
Accelerator mass spectrometry (AMS): recent experience of its use in a clinical study and the potential future of the technique.
pubmed:affiliation
Division of Bioanalysis and Drug Metabolism, Glaxo Wellcome Research and Development Ltd, Ware, UK. gcy1283@glaxowellcome.co.uk
pubmed:publicationType
Journal Article, Validation Studies